Last updated: September 2, 2026
Fludeoxyglucose F-18, commonly called FDG or [18F]FDG, is a mature PET radiopharmaceutical with broad clinical use, low molecular patent risk, and high operational barriers. Its commercial trajectory depends on PET scanner growth, oncology imaging volumes, Medicare and commercial reimbursement, hospital radiopharmacy economics, and regional manufacturing capacity. FDG is not a conventional branded drug with a single owner, patent cliff, or consolidated revenue stream. It is produced locally or regionally by multiple radiopharmacy suppliers, including Cardinal Health, PETNET Solutions, Curium, Jubilant Radiopharma, and independent hospital and commercial cyclotron operators.
What is fludeoxyglucose F-18 used for?
Fludeoxyglucose F-18 is a glucose analog labeled with the radioactive isotope fluorine-18. PET scanners detect its distribution in tissue according to glucose metabolism.
The principal clinical uses are:
| Clinical area |
Primary use |
| Oncology |
Initial staging, restaging, treatment response assessment, and recurrence detection |
| Neurology |
Evaluation of abnormal cerebral glucose metabolism, including selected dementia and seizure indications |
| Cardiology |
Assessment of myocardial glucose metabolism and myocardial viability |
| Inflammation and infection |
Selected evaluations of inflammatory or infectious processes |
| Research |
Metabolic imaging and clinical development studies |
FDG has a physical half-life of approximately 109.7 minutes. This short half-life limits inventory, requires time-sensitive delivery, and makes manufacturing location strategically important (U.S. Nuclear Regulatory Commission, n.d.).
The product is administered intravenously and is generally supplied as a sterile, preservative-free injection. The final product must meet radioactive drug quality, sterility, identity, assay, and endotoxin specifications before release.
What is the FDA regulatory status of fludeoxyglucose F-18?
FDG is an FDA-approved PET diagnostic radiopharmaceutical. FDA-approved labeling identifies its use for PET imaging in specified oncologic, cardiac, and neurologic settings. Use outside labeled indications may occur under physician-directed medical practice, but reimbursement and coverage depend on the indication, payer, and evidence base (U.S. Food and Drug Administration, n.d.-a).
FDA regulation applies to both the drug product and its manufacturing process. Commercial FDG facilities must address:
- Current good manufacturing practice requirements.
- PET drug production requirements under 21 C.F.R. Part 212.
- Sterility and aseptic processing controls.
- Radionuclide identity and purity.
- Batch release testing.
- Short-dated distribution and delivery controls.
- Facility and radioactive-material licensing requirements.
The product is distinct from conventional nonradioactive generic drugs because release and distribution must occur within a narrow time window. Manufacturing defects can result in immediate product loss because the isotope decays continuously.
What is the Orange Book status of fludeoxyglucose F-18?
FDG does not have the Orange Book profile of a high-value branded therapy. The active molecule and core diagnostic concept are long-established, and no current blockbuster-style patent estate controls the U.S. market.
The Orange Book remains relevant for identifying FDA-listed reference products and any patent or regulatory exclusivity entries associated with individual sponsors. In practical terms, the commercial barriers to FDG competition are primarily operational and regulatory rather than patent-based (U.S. Food and Drug Administration, n.d.-b).
The economic value of a supplier is therefore tied to production reliability, geographic reach, scanner contracts, scheduling integration, and reimbursement access.
How large is the fludeoxyglucose F-18 market?
There is no single authoritative global revenue figure for FDG. Suppliers generally report radiopharmaceutical, nuclear medicine, or imaging revenue at a broader level rather than disclosing FDG sales separately. Market-research estimates also differ because some reports measure only FDG, while others include the entire PET radiopharmaceutical market.
FDG remains the largest or one of the largest PET radiopharmaceutical segments by clinical volume because it is used across multiple tumor types and is available through established manufacturing networks. Its value is driven more by procedure volume than by high unit pricing.
Market structure
| Market characteristic |
FDG implication |
| Product maturity |
Mature, widely used diagnostic agent |
| Volume driver |
PET/CT and PET/MRI procedure growth |
| Price driver |
Reimbursement, local supply, delivery distance, and production economics |
| Competition |
Regional and national radiopharmacy suppliers |
| Patent exposure |
Low |
| Manufacturing barrier |
High relative to molecular complexity |
| Revenue transparency |
Low because suppliers rarely report FDG separately |
| Growth profile |
Moderate, linked to PET adoption and oncology demand |
The broader PET radiopharmaceutical market is expanding through increased use of molecular imaging, wider PET/CT capacity, improved cancer screening pathways, and the growth of targeted radioligand therapies. FDG benefits from this infrastructure expansion even as newer agents attract more investor attention.
What is driving FDG market growth?
PET/CT capacity and oncology volumes
Oncology is the primary commercial engine. FDG PET/CT is established in lymphoma, lung cancer, colorectal cancer, melanoma, head and neck cancer, esophageal cancer, and several other malignancies. Growth in cancer incidence and expanded use of PET in staging and treatment monitoring support recurring demand.
The most important volume variables are:
- Number of installed PET/CT scanners.
- Scanner utilization and operating hours.
- Physician referral patterns.
- Payer coverage for specific indications.
- Availability of nearby FDG production.
- Hospital access to radiopharmacy services.
Reimbursement
FDG demand is highly sensitive to reimbursement because the product is often purchased as part of a bundled or facility-based imaging episode. Medicare payment policy affects both the imaging center and the radiopharmacy supplier.
Payment levels vary by site of service, procedure code, geographic adjustment, hospital outpatient payment rules, and annual Medicare updates. Commercial payer rates can differ substantially from Medicare. Reimbursement pressure can reduce the amount a facility is willing to pay for the radiopharmaceutical, even when procedure volumes remain stable (Centers for Medicare & Medicaid Services, n.d.).
Expansion into community imaging
PET services are moving beyond large academic hospitals into community oncology networks and independent imaging centers. This expansion supports FDG demand but also increases the importance of route density. A supplier serving a concentrated metropolitan market can achieve better economics than one shipping individual doses over long distances.
Clinical substitution
FDG faces substitution from disease-specific PET agents in selected indications. Examples include:
- Prostate-specific membrane antigen agents for prostate cancer.
- Amyloid and tau agents for selected neurologic applications.
- Somatostatin receptor agents for neuroendocrine tumors.
- Hypoxia and other investigational tracers.
These products do not eliminate FDG’s role. They can reduce FDG use in specific diagnostic pathways while expanding the overall PET market and infrastructure base.
What is the financial trajectory for fludeoxyglucose F-18?
FDG is likely to produce a steady, volume-driven financial trajectory rather than branded-drug-style revenue growth.
Near-term trajectory
The near-term outlook is supported by:
- Continued oncology PET/CT utilization.
- Growth in community-based imaging.
- Increased scanner availability.
- Established reimbursement pathways.
- Low risk of molecule-level competition disrupting supply.
Constraints include labor costs, isotope availability, cyclotron maintenance, delivery failures, and reimbursement compression.
Medium-term trajectory
Over a three- to seven-year period, FDG revenue should track the growth of PET imaging more closely than pharmaceutical innovation. Suppliers with dense distribution networks and high scanner utilization are positioned to defend margins. Smaller operators may remain viable in local markets but face higher exposure to equipment downtime and delivery inefficiency.
FDG’s unit economics are vulnerable to decay-related waste. If a patient cancels, a scanner goes offline, or a delivery is delayed, the supplier may be unable to redeploy the dose. Scheduling software, route optimization, production automation, and close coordination with imaging centers can materially affect profitability.
Long-term trajectory
Long-term FDG growth is likely to moderate as the product reaches broad clinical penetration. The market may still expand in absolute terms if PET capacity and cancer imaging volumes rise, but newer tracers may capture a greater share of radiopharmaceutical investment and supplier attention.
The strongest financial position belongs to companies that use FDG as part of a diversified radiopharmaceutical platform. A supplier offering only FDG has less protection against indication-specific substitution and reimbursement pressure.
How much patent protection covers fludeoxyglucose F-18?
FDG has minimal remaining patent-based exclusivity risk. The underlying chemical concept, fluorine-18 labeling approach, and principal clinical applications are old technologies. Any foundational patents would have expired long ago under modern U.S. patent-term rules.
Are there formulation patents for FDG?
Potentially patentable areas can include:
- Stabilizing excipients.
- Aseptic manufacturing processes.
- Automated synthesis equipment.
- Quality-control methods.
- Packaging and dose-delivery systems.
- Specialized kits or precursor chemistry.
These rights generally protect a process, device, or formulation detail. They do not create broad exclusivity over FDG itself unless claim scope and enforceability are unusually strong.
Because FDG is radioactive and short-lived, a process patent may have limited commercial value if competitors can use alternative synthesis or release methods. Operational know-how can be more important than patent ownership.
Are there method-of-use patents for FDG?
Method-of-use patent risk is low for established FDG indications. Many conventional oncology, cardiac, and neurologic uses have been practiced and disclosed for decades. A narrowly defined imaging protocol or a combination with a specific treatment could receive patent protection, but such a right would not normally block the broader FDG market.
When does fludeoxyglucose F-18 lose exclusivity?
FDG does not have a meaningful upcoming loss-of-exclusivity event comparable to a branded small-molecule medicine. Its core exclusivity expired long before the current commercial market developed.
The relevant commercial question is not when FDG loses exclusivity. It is whether a supplier can maintain compliant production at an acceptable delivered cost.
| Exclusivity category |
FDG position |
| Active-ingredient patent |
No meaningful modern blocking patent |
| Core-use patent |
Generally expired or weak for established indications |
| Formulation patent |
Possible narrow rights, usually nonblocking |
| FDA market exclusivity |
No major current exclusivity period driving the market |
| Biosimilar exclusivity |
Not applicable |
| Generic entry |
Existing market condition rather than a future cliff |
Which companies compete in the FDG market?
Competition is fragmented geographically. Major participants and relevant categories include:
- Cardinal Health, through nuclear and radiopharmacy operations.
- PETNET Solutions, associated with Siemens Healthineers.
- Curium, a global nuclear medicine supplier.
- Jubilant Radiopharma.
- Hospital-based cyclotrons and academic radiopharmacies.
- Independent regional PET drug manufacturers.
- Integrated imaging providers that operate or contract with radiopharmacies.
Supplier competitiveness depends on production sites, cyclotron access, regulatory compliance, delivery radius, scanner relationships, and the ability to manage dose schedules. The same company may be competitive in one metropolitan area and uneconomic in another because of route density and local capacity.
Are there Paragraph IV challenges or generic entry risks for FDG?
Paragraph IV litigation risk is low. FDG is already supplied through a competitive market, and the absence of a commercially important blocking patent reduces the value of a conventional Paragraph IV strategy.
Generic-entry risk exists in a broader sense because new PET drug manufacturers can enter where they obtain FDA authorization and establish compliant production. Entry is limited by:
- Capital expenditure for cyclotron and radiopharmacy facilities.
- Validation and quality systems.
- Radioactive-material licensing.
- Qualified personnel.
- Reliable precursor and isotope supply.
- Distribution timing.
- Customer contracts.
- Dose forecasting and cancellation management.
These barriers make FDG a difficult manufacturing business despite the absence of meaningful molecule patents.
What patent litigation and licensing activity affects FDG?
FDG has no widely recognized, market-defining patent litigation comparable to litigation involving oncology therapeutics, GLP-1 drugs, or biologics. Disputes are more likely to concern facility operations, contracts, regulatory compliance, equipment, or proprietary production processes than ownership of the FDG molecule.
Licensing activity is also generally operational. Relevant arrangements may involve:
- Radiopharmacy network access.
- Cyclotron technology.
- Automated synthesis modules.
- Precursor supply.
- PET imaging software.
- Hospital or imaging-center supply agreements.
- Regional distribution rights.
Many commercial arrangements are private and are not disclosed with pricing or revenue commitments. No single licensing transaction appears to control the global FDG market.
How does FDG compare with newer PET radiopharmaceuticals?
| Factor |
FDG |
Newer targeted PET agents |
| Clinical maturity |
High |
Variable |
| Indication breadth |
Broad |
Often narrower |
| Patent protection |
Minimal |
Often substantial |
| Pricing power |
Limited to moderate |
Potentially higher |
| Supply complexity |
High |
High, often higher |
| Reimbursement maturity |
Established in many uses |
Developing |
| Commercial growth |
Volume-driven |
Launch- and adoption-driven |
| Substitution risk |
Moderate by indication |
Limited initially, but competitive |
FDG has lower pricing power but a larger installed clinical base. Newer agents may generate higher revenue per dose, while FDG provides recurring baseline volume for radiopharmacy operators.
What generic launch scenarios exist for fludeoxyglucose F-18?
A conventional generic launch scenario is largely already present. Future entrants would most likely use one of four strategies:
- Build a regional cyclotron and serve nearby imaging centers.
- Acquire an existing radiopharmacy with established routes.
- Partner with hospitals or oncology networks.
- Add FDG to a portfolio of specialty PET tracers.
A national launch is difficult because the short half-life prevents ordinary centralized distribution. The commercially rational model is regional density, redundant production, and multi-product utilization.
What is the revenue exposure for FDG suppliers?
FDG revenue exposure is highest for:
- Radiopharmacy companies with a concentrated oncology customer base.
- Imaging providers dependent on high PET/CT utilization.
- Suppliers with limited tracer diversification.
- Facilities operating near the edge of their delivery radius.
- Businesses exposed to Medicare-heavy reimbursement.
Exposure is lower for diversified platforms that sell multiple diagnostic and therapeutic radiopharmaceuticals. Such companies can use shared manufacturing, regulatory, sales, and distribution infrastructure across products.
Key Takeaways
- FDG is a mature, FDA-approved PET diagnostic with broad oncology use.
- Its core molecule and established uses have no meaningful modern patent barrier.
- Orange Book and Paragraph IV issues are secondary to manufacturing and distribution economics.
- Revenue is driven by PET/CT volumes, reimbursement, scanner capacity, and regional delivery density.
- FDG does not have a conventional patent cliff or single-product revenue disclosure.
- Growth should be steady but moderate, with newer targeted PET agents capturing more incremental innovation and pricing power.
- The strongest suppliers are diversified radiopharmaceutical companies with dense regional networks and reliable cyclotron capacity.
- Operational execution, not patent ownership, is the central competitive advantage.
FAQs About Fludeoxyglucose F-18
Is fludeoxyglucose F-18 a generic drug?
FDG is a mature small-molecule diagnostic radiopharmaceutical supplied by multiple FDA-regulated manufacturers. It is commercially competitive, but its regulatory pathway and manufacturing requirements differ from those of an ordinary oral generic drug.
Why is FDG expensive despite having no meaningful patent protection?
The cost reflects cyclotron operation, radiochemistry, sterile production, quality control, radioactive-material compliance, specialized labor, rapid delivery, and decay-related product waste.
Can FDG be shipped nationally from one manufacturing site?
Usually not on an economically practical basis. Its approximately 110-minute half-life makes regional production and distribution more efficient.
Will prostate cancer PET agents replace FDG?
They may reduce FDG use in selected prostate cancer pathways, but they do not replace FDG across oncology, neurology, cardiology, and other imaging applications.
What is the biggest investment risk in the FDG market?
The main risks are reimbursement pressure, PET utilization weakness, production downtime, delivery failures, and competition from newer tracers. Patent expiry is not the central risk.
References
Centers for Medicare & Medicaid Services. (n.d.). Hospital outpatient prospective payment system and ambulatory surgical center payment system. https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient
U.S. Food and Drug Administration. (n.d.-a). Fludeoxyglucose F 18 injection prescribing information. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Nuclear Regulatory Commission. (n.d.). Medical use of byproduct material and radionuclide information. https://www.nrc.gov/materials/miau/med-use.html
U.S. Pharmacopeia. (2023). General chapter <823>: Positron emission tomography drugs for compounding, investigational, and research uses. United States Pharmacopeial Convention.
